Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$29.18 -1.4%	$28.18	$23.23 ▼ $42.29	$937.61M	0.63	413,394 shs	227,489 shs
EPZM Epizyme	$1.47	$1.47	$0.41 ▼ $5.80	$247.44M	-0.41	3.23 million shs	7,960 shs
NRIX Nurix Therapeutics	$11.93 -0.3%	$10.62	$8.18 ▼ $29.56	$909.50M	2.15	882,457 shs	779,250 shs
PAHC Phibro Animal Health	$23.93 -2.4%	$21.25	$16.16 ▼ $26.55	$969.98M	0.74	204,586 shs	152,026 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	-1.42%	-3.38%	+0.38%	-0.95%	-8.47%
EPZM Epizyme	0.00%	0.00%	0.00%	0.00%	0.00%
NRIX Nurix Therapeutics	-0.25%	-6.65%	+24.53%	-12.21%	-27.70%
PAHC Phibro Animal Health	-2.37%	-0.62%	+2.44%	+12.61%	+34.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	3.9951 of 5 stars	3.4	1.0	0.0	3.0	2.1	0.8	2.5
EPZM Epizyme	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	2.2401 of 5 stars	4.4	1.0	0.0	0.0	2.5	0.8	0.0
PAHC Phibro Animal Health	3.7442 of 5 stars	0.8	4.0	2.5	1.1	2.5	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	49.93% Upside
EPZM Epizyme	0.00	N/A	N/A	N/A
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.18	152.95% Upside
PAHC Phibro Animal Health	1.50	Reduce	$20.00	-16.42% Downside

Current Analyst Ratings Breakdown

Latest EPZM, NRIX, PAHC, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/9/2025	NRIX Nurix Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $25.00
4/9/2025	NRIX Nurix Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $35.00
4/9/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
4/2/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/24/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/17/2025	NRIX Nurix Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$664.28M	1.41	$10.57 per share	2.76	$5.99 per share	4.87
EPZM Epizyme	$37.43M	6.61	N/A	N/A	($0.54) per share	-2.72
NRIX Nurix Therapeutics	$56.42M	16.12	N/A	N/A	$7.44 per share	1.60
PAHC Phibro Animal Health	$1.19B	0.81	$2.20 per share	10.87	$6.09 per share	3.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$48.15M	$1.22	12.58	4.85	N/A	14.78%	104.67%	18.38%	8/6/2025 (Estimated)
EPZM Epizyme	-$251.12M	-$1.72	N/A	N/A	N/A	-391.90%	-2,459.33%	-69.74%	N/A
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-354.85%	-53.65%	-38.59%	7/10/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	49.85	11.40	0.45	1.75%	25.35%	6.21%	8/27/2025 (Estimated)

Latest EPZM, NRIX, PAHC, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.73	N/A	N/A	N/A	$16.26 million	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EPZM Epizyme	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.01%	N/A	61.54%	N/A

Latest EPZM, NRIX, PAHC, and COLL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.43	0.97	0.88
EPZM Epizyme	N/A	5.35	5.19
NRIX Nurix Therapeutics	N/A	6.46	6.46
PAHC Phibro Animal Health	2.99	3.20	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
EPZM Epizyme	76.45%
NRIX Nurix Therapeutics	N/A
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
EPZM Epizyme	23.40%
NRIX Nurix Therapeutics	7.40%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	30.97 million	Optionable
EPZM Epizyme	250	168.33 million	128.97 million	Optionable
NRIX Nurix Therapeutics	300	76.24 million	70.42 million	Optionable
PAHC Phibro Animal Health	1,860	40.53 million	20.22 million	Optionable

EPZM, NRIX, PAHC, and COLL Headlines

Recent News About These Companies

PAHC vs. BSX: Which Stock Should Value Investors Buy Now?

June 13 at 12:41 PM | zacks.com

4 Stocks Trading Near 52-Week High With More Upside Potential

June 13 at 12:36 PM | zacks.com

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

June 13 at 10:41 AM | zacks.com

173,016 Shares in Phibro Animal Health Co. (NASDAQ:PAHC) Purchased by Axecap Investments LLC

June 12 at 6:53 AM | marketbeat.com

Bank of America Corp DE Cuts Stake in Phibro Animal Health Co. (NASDAQ:PAHC)

June 12 at 3:07 AM | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 16,917 Shares of Phibro Animal Health Co. (NASDAQ:PAHC)

June 9, 2025 | marketbeat.com

Phibro (PAHC) Up 7.4% Since Last Earnings Report: Can It Continue?

June 6, 2025 | zacks.com

Why Phibro Animal Health (PAHC) is a Top Momentum Stock for the Long-Term

June 6, 2025 | zacks.com

Public Employees Retirement System of Ohio Buys New Position in Phibro Animal Health Co. (NASDAQ:PAHC)

June 5, 2025 | marketbeat.com

Zacks.com featured highlights Urban Outfitters, Phibro Animal Health and Strattec Security

June 5, 2025 | finance.yahoo.com

Mackenzie Financial Corp Acquires New Holdings in Phibro Animal Health Co. (NASDAQ:PAHC)

June 4, 2025 | marketbeat.com

3 Stocks Showing Positive Momentum Despite Trade Tensions

June 3, 2025 | zacks.com

Summit Global Investments Has $811,000 Stake in Phibro Animal Health Co. (NASDAQ:PAHC)

June 1, 2025 | marketbeat.com

Ameriprise Financial Inc. Purchases 21,576 Shares of Phibro Animal Health Co. (NASDAQ:PAHC)

June 1, 2025 | marketbeat.com

Jane Street Group LLC Trims Stock Position in Phibro Animal Health Co. (NASDAQ:PAHC)

June 1, 2025 | marketbeat.com

Kings Path Partners LLC Buys New Stake in Phibro Animal Health Co. (NASDAQ:PAHC)

May 31, 2025 | marketbeat.com

Millennium Management LLC Has $4.36 Million Position in Phibro Animal Health Co. (NASDAQ:PAHC)

May 31, 2025 | marketbeat.com

Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock

May 29, 2025 | zacks.com

Phibro (PAHC) is an Incredible Growth Stock: 3 Reasons Why

May 28, 2025 | zacks.com

PAHC or BSX: Which Is the Better Value Stock Right Now?

May 28, 2025 | zacks.com

Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?

May 28, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPZM, NRIX, PAHC, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$29.18 -0.42 (-1.42%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$29.18 +0.00 (+0.02%)

As of 06/13/2025 04:04 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Epizyme NASDAQ:EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Nurix Therapeutics NASDAQ:NRIX

$11.93 -0.03 (-0.25%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$12.12 +0.19 (+1.58%)

As of 06/13/2025 05:21 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Phibro Animal Health NASDAQ:PAHC

$23.93 -0.58 (-2.37%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$23.25 -0.68 (-2.86%)

As of 06/13/2025 04:57 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time